Franklin, MA-based Echo Therapeutics is speeding up the launch of its non-invasive drug delivery system and announced plans to list on a national exchange. The company, along with its partners Fendale Pharma Group, received feedback from the FDA that will require "minor" changes to the company's glucose monitoring system, Echo announced in a release.
The company is developing its Prelude SkinPrep System for transdermal drug delivery and, as a result of feedback from the FDA, is now accelerating Prelude toward commercial launch, the company said. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. The device is meant to permeate the skin in preparation for transdermal protein (or large molecule) drug delivery. In the future, it could lead to prick-free blood glucose readings.
The company says that it is preparing to "apply for listing on a national exchange," although it did not specify which one.
- read the Echo release